GSA Capital Partners LLP Cuts Position in Haemonetics Co. (HAE)

GSA Capital Partners LLP reduced its stake in shares of Haemonetics Co. (NYSE:HAE) by 72.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,107 shares of the medical instruments supplier’s stock after selling 42,834 shares during the period. GSA Capital Partners LLP’s holdings in Haemonetics were worth $1,846,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of HAE. CIBC Asset Management Inc purchased a new stake in Haemonetics in the 3rd quarter worth approximately $219,000. Granahan Investment Management Inc. MA purchased a new stake in Haemonetics in the 2nd quarter worth approximately $229,000. Wealth Alliance Advisory Group LLC purchased a new stake in Haemonetics in the 3rd quarter worth approximately $229,000. Welch & Forbes LLC purchased a new stake in shares of Haemonetics during the 3rd quarter valued at $229,000. Finally, Oakbrook Investments LLC purchased a new stake in shares of Haemonetics during the 3rd quarter valued at $229,000. Hedge funds and other institutional investors own 98.37% of the company’s stock.

Shares of NYSE HAE opened at $108.40 on Tuesday. Haemonetics Co. has a 52-week low of $56.00 and a 52-week high of $117.56. The firm has a market cap of $5.54 billion, a PE ratio of 57.97, a P/E/G ratio of 3.68 and a beta of 1.09. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.92 and a quick ratio of 2.06.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.02. Haemonetics had a net margin of 2.26% and a return on equity of 16.04%. The company had revenue of $241.58 million during the quarter, compared to analysts’ expectations of $233.44 million. During the same period in the previous year, the company earned $0.48 EPS. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. As a group, sell-side analysts expect that Haemonetics Co. will post 2.33 EPS for the current fiscal year.

HAE has been the subject of several research reports. Jefferies Financial Group reissued a “buy” rating and set a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 7th. Barrington Research reissued a “buy” rating and set a $127.00 price objective on shares of Haemonetics in a research note on Friday, October 5th. TheStreet cut shares of Haemonetics from a “b” rating to a “c+” rating in a research note on Monday, August 20th. Morgan Stanley boosted their price objective on shares of Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, August 8th. Finally, Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price objective for the company in a research note on Friday, October 12th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $113.20.

In related news, Director Pedro P. Granadillo sold 12,322 shares of Haemonetics stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $114.50, for a total transaction of $1,410,869.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO William P. Mr. Burke sold 841 shares of Haemonetics stock in a transaction on Thursday, October 25th. The shares were sold at an average price of $46.76, for a total transaction of $39,325.16. The disclosure for this sale can be found here. Insiders have sold a total of 62,653 shares of company stock worth $6,973,391 in the last 90 days. Company insiders own 1.04% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2018/12/04/gsa-capital-partners-llp-cuts-position-in-haemonetics-co-hae.html.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Story: What kind of dividend yield to CEF’s pay?

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit